MARKET

WINT

WINT

Windtree Therapeutics Inc
NASDAQ
2.050
-0.005
-0.24%
After Hours: 2.010 -0.04 -1.95% 19:49 03/14 EDT
OPEN
2.050
PREV CLOSE
2.055
HIGH
2.110
LOW
1.980
VOLUME
37.02K
TURNOVER
--
52 WEEK HIGH
737.44
52 WEEK LOW
1.780
MARKET CAP
1.54M
P/E (TTM)
-0.0100
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at WINT last week (0303-0307)?
Weekly Report · 6d ago
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On?
Benzinga · 03/04 14:38
Windtree Therapeutics announces notice of allowance from USPTO for istaroxime
TipRanks · 03/04 13:06
WINDTREE ANNOUNCES ISTAROXIME NOTICE OF ALLOWANCE FROM THE U.S. PATENT AND TRADEMARK OFFICE FOR ACUTE HEART FAILURE
Reuters · 03/04 13:00
Weekly Report: what happened at WINT last week (0224-0228)?
Weekly Report · 03/03 11:34
Windtree Therapeutics files patent in India for cardiac arrythmia therapy
TipRanks · 02/27 13:31
WINDTREE FILES ISTAROXIME CARDIOGENIC SHOCK AND PREVENTION OF ARRYTHMIAS PATENT FOR INDIA
Reuters · 02/27 13:06
Windtree Announces The Company Has Filed A National Phase Patent Application With The Indian Patent Office Claiming Priority To PCT/US2024/058923 Entitled, "ISTAROXIME AND DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA."
Benzinga · 02/27 13:04
More
About WINT
More
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.
Recently
Symbol
Price
%Change

Webull offers Windtree Therapeutics Inc stock information, including NASDAQ: WINT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WINT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading WINT stock methods without spending real money on the virtual paper trading platform.